Recent studies have proposed several genetic drivers of innate or acquired resistance to ICB therapy, some of which confirm that the B2M gene impedes the success of cancer immunotherapy by generating MHC class I-loss tumor variants. This evidence concerns the gene B2M and neoplasm.